Doctor profile · Federal record
Dr. Daniel Elbogdadi, MD
Rheumatology Physician (CMS: Rheumatology) · Fairfax, VA
- NPI 1528186285
- Accepts Medicare
- MIPS 77.1 / 100 · 2023
- 25 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
8270 Willow Oaks Corporate Dr Ste 150
Fairfax, VA 220314530
(301) 942-7600
fax (703) 573-7767 - Mailing address
-
7361 Calhoun Pl Ste 600
Rockville, MD 208552788
Credentials & registration
- NPI registered
- March 2007 — 19 yrs on file
- Profile last updated
- February 5, 2026
- Year of graduation
- 2001 — 25 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Maryland #D0077404
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1528186285. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
75,567
Distinct HCPCS
10
Medicare allowed
$956,407
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J3262 |
Injection, tocilizumab, 1 mg | 25,120 | 20 | $6 | |
J0717 |
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18,000 | 14 | $5 | |
J3111 |
Injection, romosozumab-aqqg, 1 mg | 12,180 | 26 | $10 | |
J0897 |
Injection, denosumab, 1 mg | 7,080 | 106 | $23 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 4,500 | 15 | $13 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 1,350 | 14 | $33 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 1,036 | 477 | $145 | |
36415 |
Insertion of needle into vein for collection of blood sample | 678 | 373 | $8 | |
80053 |
Blood test, comprehensive group of blood chemicals | 645 | 363 | $10 | |
86140 |
Measurement c-reactive protein for detection of infection or inflammation | 530 | 277 | $5 |
In context: peer comparison
Among 2 peers in this city , average services per provider: 1,327. This provider delivers 57× the peer median.Open Payments
Industry payments received
All-time total
$535
Transactions
10
Manufacturers
6
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $155.13 | |
| Novartis Pharmaceuticals Corporation | 1 | $137.40 | |
| Amgen Inc. | 2 | $97.49 | |
| Lilly USA, LLC | 2 | $95.57 | |
| ABBVIE INC. | 2 | $35.30 | |
| UCB, Inc. | 1 | $13.79 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
881
Patients
238
Total drug cost
$272,251
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Prednisone | Generic | 208 | 50 | $1,745 |
| Hydroxychloroquine Sulfate | Generic | 118 | 36 | $6,488 |
| Methotrexate (Methotrexate Sodium) | Brand | 104 | 30 | $2,595 |
| Gabapentin | Generic | 67 | 19 | $797 |
| Allopurinol | Generic | 60 | 17 | $925 |
| Duloxetine Hcl | Generic | 43 | 12 | $1,401 |
| Diclofenac Sodium | Generic | 42 | 12 | $1,656 |
| Pregabalin | Generic | 39 | 0 | $1,096 |
| Tramadol Hcl | Generic | 37 | 13 | $379 |
| Methylprednisolone | Generic | 32 | 23 | $1,479 |
Frequently asked questions
What is Dr. Daniel Elbogdadi's medical specialty?
Dr. Daniel Elbogdadi practices Rheumatology Physician in Fairfax, VA.
Where does Dr. Daniel Elbogdadi practice?
Dr. Daniel Elbogdadi practices at 8270 Willow Oaks Corporate Dr Ste 150, Fairfax, VA 220314530. Office phone: 3019427600.
What is Dr. Daniel Elbogdadi's NPI?
Dr. Daniel Elbogdadi's National Provider Identifier (NPI) is 1528186285, issued by NPPES.
Does Dr. Daniel Elbogdadi accept Medicare assignment?
Yes. Dr. Daniel Elbogdadi accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Daniel Elbogdadi commonly perform?
Top Medicare-reported procedures in 2023: Injection, tocilizumab, 1 mg (HCPCS J3262); Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0717); Injection, romosozumab-aqqg, 1 mg (HCPCS J3111). Source: CMS Medicare Physician & Other Practitioners file.